- Conditions
- Chronic Rhinosinusitis (Diagnosis)
- Interventions
- Comparison of medication administration for pain control
- Other
- Lead sponsor
- University of Illinois Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1441–1464
of 17,851
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Non Squamous Lung Cancer
- Interventions
- treatment
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 343 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 84
- States / cities
- Beverly Hills, California • Fontana, California • Loma Linda, California + 53 more
- Conditions
- Grade 2 Meningioma, Intracranial Meningioma
- Interventions
- Biospecimen Collection, Clinical Observation, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Proton Beam Radiation Therapy, Quality-of-Life Assessment
- Procedure · Other · Radiation
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2032
- U.S. locations
- 198
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 162 more
- Conditions
- Multiple Myeloma
- Interventions
- Arlocabtagene Autoleucel
- Biological
- Lead sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Little Rock, Arkansas + 33 more
- Conditions
- Hypercholesterolemia
- Interventions
- Alirocumab, Atorvastatin, Ezetimibe, Rosuvastatin, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 355 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 56
- States / cities
- Mobile, Alabama • Chandler, Arizona • Tucson, Arizona + 53 more
- Conditions
- Opioid-Related Disorders, Substance-Related Disorders
- Interventions
- 20% N2O, 30% N2O, 40% N2O
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 21 Years to 37 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1993 – 1995
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Postoperative Pain
- Interventions
- opioid pain pills
- Drug
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 304 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- delandistrogene moxeparvovec, placebo
- Genetic
- Lead sponsor
- Sarepta Therapeutics, Inc.
- Industry
- Eligibility
- Male only
- Enrollment
- 148 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 14
- States / cities
- Little Rock, Arkansas • Palo Alto, California • Sacramento, California + 11 more
- Conditions
- Carcinoma, Non-Small-Cell Lung, Lung Cancer, Neoplasms, Lung, Neoplasms, Pulmonary
- Interventions
- talabostat, pemetrexed
- Drug
- Lead sponsor
- Point Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 101
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 84 more
- Conditions
- Brain and Central Nervous System Tumors, Neurotoxicity
- Interventions
- temozolomide, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy
- Drug · Radiation
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 540 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2026
- U.S. locations
- 168
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 117 more
- Conditions
- Seasonal Affective Disorder (SAD)
- Interventions
- Investigational Seasonal Affective Disorder (SAD) Drug
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 47
- States / cities
- Homer, Alaska • New Haven, Connecticut • Newark, Delaware + 39 more
- Conditions
- Knee Osteoarthritis
- Interventions
- Vitamin D, Control
- Drug
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 137 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Non-obstructive Hypertrophic Cardiomyopathy
- Interventions
- IMB-1018972, Placebo
- Drug
- Lead sponsor
- Imbria Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 13
- States / cities
- La Jolla, California • Los Angeles, California • San Francisco, California + 10 more
- Conditions
- Preeclampsia
- Interventions
- Recombinant human antithrombin (ATryn), Normal Saline 0.9%
- Biological · Other
- Lead sponsor
- rEVO Biologics
- Industry
- Eligibility
- 16 Years and older · Female only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 19 more
- Conditions
- Treatment Outcome
- Interventions
- Vortioxetine, Escitalopram, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 447 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 53
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 50 more
- Conditions
- HIV Infections
- Interventions
- Aldesleukin
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 3 Years to 12 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2001
- U.S. locations
- 14
- States / cities
- Long Beach, California • San Francisco, California • Aurora, Colorado + 8 more
- Conditions
- Crohn's Disease
- Interventions
- Adalimumab
- Biological
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 777 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 63
- States / cities
- Huntsville, Alabama • Jacksonville, Alabama • La Jolla, California + 56 more
- Conditions
- Fetal Growth Restriction, Growth Discordancy
- Interventions
- Not listed
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 171 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2014
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Long Beach, California • Orange, California + 6 more
- Conditions
- Severe Hypertriglyceridemia
- Interventions
- K-877, Fenofibrate, Placebo (for K-877), Placebo (for Fenofibrate)
- Drug
- Lead sponsor
- Kowa Research Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 551 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 110
- States / cities
- Birmingham, Alabama • Hamilton, Alabama • Huntsville, Alabama + 94 more
- Conditions
- Open-angle Glaucoma, Ocular Hypertension
- Interventions
- AGN-193408 SR, Lumigan, Sham Administration, Lumigan Vehicle
- Drug · Other
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 42
- States / cities
- Sun City, Arizona • Glendale, California • Inglewood, California + 38 more
- Conditions
- Childhood Solid Neoplasm, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Neuroblastoma
- Interventions
- Crizotinib, Cyclophosphamide, Dexrazoxane Hydrochloride, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Questionnaire Administration, Topotecan Hydrochloride, Vincristine Sulfate
- Drug · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 13 Months to 21 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Los Angeles, California • Orange, California + 18 more
- Conditions
- Acute Promyelocytic Leukemia
- Interventions
- Tamibarotene
- Drug
- Lead sponsor
- CytRx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Houston, Texas
- Conditions
- Lymphoma
- Interventions
- Inotuzumab Ozogamicin (CMC-544)
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Loma Linda, California • Mission Hills, California + 12 more
- Conditions
- Primary Sclerosing Cholangitis
- Interventions
- Elafibranor, Placebo
- Drug · Other
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 69
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Coronado, California + 51 more